



Press Release
24 April 2009

Option agreement for ChronSeal[®] has been signed with Japan's leading dermatology company

As earlier disclosed Tripep through its partner Kringle Pharma has signed a letter of intent with the Japanese specialty pharma company Maruho regarding ChronSeal[®], Tripep's and Kringle Pharma's jointly owned product for the treatment of chronic leg wounds. Kringle Pharma/Tripep has now moved on and signed an option agreement giving Maruho the first right to evaluate the results from the ongoing phase I/II study and to negotiate the rights for sale in the Japanese market. Some remuneration will be paid for the option but the amount cannot be disclosed according to the agreement. The remuneration has no material impact on Tripep's financial position.

For more information, please contact:

Anders Vahlne, CEO & Head of Research, Tripep AB
Tel: +46 8 5858 1313, Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se

About Tripep

Tripep develops drugs against chronic disease based on proprietary and other parties' patented and patent pending technologies. Tripep is focusing on the following research projects; wound healing therapy ChronSeal[®] and a therapeutic vaccine against Hepatitis C, named ChronVac-C[®], plus the RAS[®] technology platform. The Tripep share is admitted to trade on First North. Remium AB is Certified Adviser for Tripep AB. For more information, please refer to the company's website: www.tripep.se.

In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.